What is the primary purpose of this 10-K filing for Pfizer Inc.?

The primary purpose of this 10-K filing is to provide a comprehensive overview of Pfizer Inc.'s financial performance, business operations, and strategic direction for the fiscal year ending December 30, 1996, to shareholders and the investing public.

What kind of information would an investor typically find in this report that is relevant to Pfizer's business?

Investors would typically look for detailed financial statements (income statement, balance sheet, cash flow), management's discussion and analysis of financial condition and results of operations, information on significant products and their market performance, details on research and development efforts and pipeline, competitive landscape, and any material legal or regulatory disclosures.

Given the filing date of March 1997, what key trends in the pharmaceutical industry might have been influencing Pfizer's performance?

In 1996-1997, the pharmaceutical industry was likely influenced by factors such as increasing R&D costs, patent expirations of blockbuster drugs, the rise of biotechnology, evolving regulatory landscapes (e.g., FDA approval processes), and growing market globalization. Companies like Pfizer would have been navigating these dynamics to maintain growth and profitability.

Where can I find the actual financial data and detailed business segments from this 10-K filing?

The provided text is a directory listing of the filing on the SEC's EDGAR system, not the full content of the report itself. To access the detailed financial data, business segments, and narrative sections, you would need to locate and review the actual filing documents (e.g., the .txt or HTML files) within the SEC's EDGAR database using the provided filing information (company name, ticker, filing date).

PFE 10-K FY1996 Annual Report — Revenue, Net Income, EPS

Summary

Pfizer Inc. filed its annual report on March 27, 1997, for the fiscal year ending December 30, 1996. As a leading pharmaceutical company, this filing provides insights into the company's financial performance, strategic direction, and operational highlights during a pivotal period in the healthcare industry. Investors would look to this report for a detailed understanding of Pfizer's product pipeline, market performance of key drugs, and its approach to research and development, which are critical drivers of growth in the pharmaceutical sector. While specific financial figures and operational details are not present in the provided directory listing, an investor would typically find information on revenue, profitability, segment performance (e.g., by therapeutic area or geographic region), significant acquisitions or divestitures, and any material legal or regulatory matters. The period covered by this report precedes significant advancements in many therapeutic areas, making the review of Pfizer's 1996 performance crucial for understanding its trajectory into the late 1990s and early 2000s.

Key Highlights

1The filing is Pfizer Inc.'s 10-K Annual Report for the fiscal year ending December 30, 1996.
2The report was filed with the SEC on March 27, 1997.
3As a pharmaceutical company, investors would typically expect to find details on product sales, research and development activities, and financial performance.
4This report provides a snapshot of Pfizer's business operations and financial health as of year-end 1996.
5Information regarding specific drug performance, pipeline advancements, and market strategies would be of key interest to investors.
6The filing serves as a primary source for understanding the company's strategic priorities and operational achievements in the year prior to the 2000s.

PFIZER INC Annual Report, Year Ended Dec 31, 1996

Summary

Key Highlights

Frequently Asked Questions